The CLL International Prognostic Index (CLL-IPI) was formulated by analyzing clinical, biological, and genetic parameters including age, clinical stage, TP53 status, IGHV status, and serum β2M, utilizing data from patients enrolled in eight randomized clinical trials in 2016. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.